GSK CEO Emma Walmsley said on Thursday that the British drugmaker's respiratory syncytial virus (RSV) vaccine Arexvy would generate more than 1 billion pounds ($1.26 billion) in its first year on the ...
As the battle between new respiratory syncytial virus (RSV) vaccines heats up, GSK is “delighted” with the progress it’s made ...
The AstraZeneca office building in Brussels, Friday, Jan. 29, 2021. Amid a dispute over expected shortfalls, the European Union is looking at legal ways to guarantee the delivery of all the COVID-19 ...
Preventive treatment is now available for the respiratory syncytial virus, which affects 64 million people annually. But drug ...
Of the roughly 14,000 doses requested by CT, only about 10,000 have been received and distributed, CT public health officials ...
US health authorities on Thursday, November 9, approved the world's first vaccine for chikungunya, a virus spread by infected mosquitoes that the Food and Drug Administration called "an emerging ...
The Food and Drug Adminstration (FDA) approved the first vaccine for the mosquito-born illness chikungunya on Thursday, a key step in fighting the dangerous virus. Chikungunya virus infects more ...
LONDON (Reuters) -GSK CEO Emma Walmsley said on Thursday that the British drugmaker's respiratory syncytial virus (RSV) vaccine was now expected to generate more than 1 billion pounds ($1.26 billion) ...
The US Food and Drug Administration said Thursday that it has approved the first vaccine to prevent disease caused by the chikungunya virus. Chikungunya, a mosquito-borne disease whose name in the ...
Nov. 10, 2023 -- The FDA on Thursday approved the first vaccine for the chikungunya virus, which is transmitted to humans through mosquito bites. The vaccine, called Ixchiq and produced by Valneva ...
US health authorities on Thursday approved the world's first vaccine for chikungunya, a virus spread by infected mosquitoes that the Food and Drug Administration called "an emerging global health ...
